These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

406 related items for PubMed ID: 34673645

  • 21. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lu S, Ye M, Ding L, Tan F, Fu J, Wu B.
    Oncotarget; 2017 Feb 07; 8(6):9996-10006. PubMed ID: 28036283
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T, Hata A, Tomioka H, Tanaka K, Kaji R, Fujita S, Tomii K, Katakami N.
    Lung Cancer; 2014 Nov 07; 86(2):213-8. PubMed ID: 25304185
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Comparison of clinical outcomes of patients with non-small cell lung cancer harboring different types of epidermal growth factor receptor sensitive mutations after first-line EGFR-TKI treatment].
    Liu JJ, Zhang S, Wu CJ, Ma LX, Liu Y, Li H, Cui HX, Cheng Y.
    Zhonghua Zhong Liu Za Zhi; 2016 Mar 23; 38(3):211-7. PubMed ID: 26988828
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Clinical effects for patients with recurrent advanced non-small cell lung cancer treated with icotinib hydrochloride].
    Nong J, Qin N, Wang J, Yang X, Zhang H, Wu Y, Lv J, Zhang Q, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2013 May 23; 16(5):240-5. PubMed ID: 23676980
    [Abstract] [Full Text] [Related]

  • 30. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T, Mori M, Yano Y, Uchida J, Nishino K, Kaji R, Hata A, Hattori Y, Urata Y, Kaneda T, Tachihara M, Imamura F, Katakami N, Negoro S, Morita S, Yokota S.
    Anticancer Res; 2015 Jul 23; 35(7):3885-91. PubMed ID: 26124334
    [Abstract] [Full Text] [Related]

  • 31. [Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified].
    Li X, Qin N, Wang J, Yang X, Zhang X, Lv J, Wu Y, Zhang H, Nong J, Zhang Q, Zhang S.
    Zhongguo Fei Ai Za Zhi; 2015 Dec 23; 18(12):734-9. PubMed ID: 26706949
    [Abstract] [Full Text] [Related]

  • 32. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
    Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL.
    Lancet Respir Med; 2017 Sep 23; 5(9):707-716. PubMed ID: 28734822
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    Liang W, Wu X, Fang W, Zhao Y, Yang Y, Hu Z, Xue C, Zhang J, Zhang J, Ma Y, Zhou T, Yan Y, Hou X, Qin T, Dinglin X, Tian Y, Huang P, Huang Y, Zhao H, Zhang L.
    PLoS One; 2014 Sep 23; 9(2):e85245. PubMed ID: 24533047
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.
    Shao L, Zhang B, He C, Lin B, Song Z, Lou G, Yu X, Zhang Y.
    Chin Med J (Engl); 2014 Sep 23; 127(2):266-71. PubMed ID: 24438614
    [Abstract] [Full Text] [Related]

  • 36. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL, Han G, Peng M, Weng YM, Yuan JP, Yang GF, Yu JM, Song QB.
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec 23; 37(6):864-872. PubMed ID: 29270745
    [Abstract] [Full Text] [Related]

  • 37. Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer.
    Kaneda T, Yoshioka H, Tamiya M, Tamiya A, Hata A, Okada A, Niwa T, Shiroyama T, Kanazu M, Ishida T, Katakami N.
    BMC Cancer; 2018 Jan 02; 18(1):6. PubMed ID: 29291705
    [Abstract] [Full Text] [Related]

  • 38. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
    Ren GJ, Zhao YY, Zhu YJ, Xiao Y, Xu JS, Shan B, Zhang L.
    Chin Med J (Engl); 2011 Jan 02; 124(1):19-25. PubMed ID: 21362302
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
    Baek JH, Sun JM, Min YJ, Cho EK, Cho BC, Kim JH, Ahn MJ, Park K.
    Lung Cancer; 2015 Feb 02; 87(2):148-54. PubMed ID: 25498243
    [Abstract] [Full Text] [Related]

  • 40. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
    He J, Su C, Liang W, Xu S, Wu L, Fu X, Zhang X, Ge D, Chen Q, Mao W, Xu L, Chen C, Hu B, Shao G, Hu J, Zhao J, Liu X, Liu Z, Wang Z, Xiao Z, Gong T, Lin W, Li X, Ye F, Liu Y, Ma H, Huang Y, Zhou J, Wang Z, Fu J, Ding L, Mao L, Zhou C.
    Lancet Respir Med; 2021 Sep 02; 9(9):1021-1029. PubMed ID: 34280355
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.